Literature DB >> 24820511

Haematuria: from identification to treatment.

Kathryn King1, Martin Steggall2.   

Abstract

Haematuria has a prevalence of 0.1% to 2.6%. Potential diagnoses may include infection, kidney stones, trauma, exercise or spurious causes, such as foods, drugs or menstruation, and a tumour. Approximately 20% of patients with haematuria have a urological tumour, with a further 20% found to have a significant underlying pathology. Haematuria is subsequently known as the 'classic presentation' of bladder cancer with 70-80% of patients experiencing painless, gross (visible) haematuria. However, in all cases of visible haematuria, a tumour should be suspected until proven otherwise. A patient with visible haematuria requires urgent, stringent investigation, warranting specialist assessment and subsequent selective referral through a series of patient-centred investigations at a haematuria clinic. One-stop clinics have been shown to improve the patient experience in early diagnosis of potentially life-threatening conditions. Yet despite morbidity and mortality from bladder cancer increasing, the haematuria service has remained largely unchanged for several decades. This paper will discuss the tests and investigations that need to be undertaken in an individual with either visible or non-visible haematuria, and outline the care that is needed to support patients through the investigation process, with special focus on bladder tumour.

Entities:  

Mesh:

Year:  2014        PMID: 24820511     DOI: 10.12968/bjon.2014.23.Sup9.S28

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  3 in total

1.  Upper Tract Imaging in Patients with Initial or Terminal Hematuria Suggestive of Bleeding from the Lower Urinary Tract: How Often is the Upper Urinary Tract Responsible for the Hematuria?

Authors:  Omar W S Al-Mula Abed; Shalom J Srirangam; Guy D Wemyss-Holden
Journal:  Oman Med J       Date:  2018-09

2.  An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer.

Authors:  Andrew J Sutton; John V Lamont; R Mark Evans; Kate Williamson; Declan O'Rourke; Brian Duggan; Gurdeep S Sagoo; Cherith N Reid; Mark W Ruddock
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

3.  The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.

Authors:  Jay D Raman; Laimonis Kavalieris; Badrinath Konety; Sima Porten; Siamak Daneshmand; Yair Lotan; Ronald Loo
Journal:  J Urol       Date:  2021-08-05       Impact factor: 7.450

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.